Data Sheet (Cat.No.T16770)

TargetMol

Ro 41-1049 hydrochloride

Chemical Properties



CAS No. :	127917-66-2
Formula:	C12H13ClFN3OS
Molecular Weight:	301.77
Storage:	Powder: -20°C for 3 years | In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.

Biological Description

Description	Ro 41-1049 hydrochloride is a reversible and selective inhibitor of monoamine oxidase-A (Kd: 16.5 and 64.4 nM, respectively).
Targets(IC50)	MAO,Monoamine Oxidase
In vivo	Ro 41-1049 (20 mg/kg) pretreatment significantly increases dopamine formation following L-dopa administration (100 mg/kg IP) while decreasing the formation of 3,4-dihydroxyphenylacetic acid and homovanillic acid. Ro 41-1049 (1-50 mg/kg; intraperitoneal injection; for 3 hours; Sprague-Dawley rats) treatment inhibits dopamine metabolite formation and increases dopamine levels in a dose-dependent

Solubility Information

Solubility	DMSO: 32 mg/mL (106.04 mM),Sonication is recommended. H2O: 25 mg/mL (82.84 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (6.63 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.3138 mL	16.5689 mL	33.1378 mL
5 mM	0.6628 mL	3.3138 mL	6.6276 mL
10 mM	0.3314 mL	1.6569 mL	3.3138 mL
50 mM	0.0663 mL	0.3314 mL	0.6628 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Cesura AM, et al. Characterization of the binding of [3H]Ro 41-1049 to the active site of human monoamine oxidase-A. Mol Pharmacol. 1990 Mar;37(3):358-66.
Brannan T, et al. Effect of a selective MAO-A inhibitor (Ro 41-1049) on striatal L-dopa and dopamine metabolism: an in vivo study. J Neural Transm Park Dis Dement Sect. 1994;8(1-2):99-105.